Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai, Maharashtra, India.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):751-762. doi: 10.1007/s00210-023-02681-5. Epub 2023 Aug 31.
The microbiome is increasingly implicated in playing a role in physiology and pharmacology; in this review, we investigate the literature on the possibility of bacterial influence on the pharmacology of anti-asthmatic drugs, and the potential impact this has on asthmatic patients. Current knowledge in this area of research reveals an interaction between the gut and lung microbiome and the development of asthma. The influence of microbiome on the pharmacokinetics and pharmacodynamics of anti-asthmatic drugs is limited; however, understanding this interaction will assist in creating a more efficient treatment approach. This literature review highlighted that bioaccumulation and biotransformation in the presence of certain gut bacterial strains could affect drug metabolism in anti-asthmatic drugs. Furthermore, the bacterial richness in the lungs and the gut can influence drug efficacy and could also play a role in drug response. The implications of the above findings suggest that the microbiome is a contributing factor to an individuals' pharmacological response to anti-asthmatic drugs. Hence, future directions for research should follow investigating how these processes affect asthmatic patients and consider the role of the microbiome on drug efficacy and modify treatment guidelines accordingly.
微生物组越来越被认为在生理学和药理学中发挥作用；在这篇综述中，我们调查了关于细菌对哮喘药物药理学影响的可能性的文献，以及这对哮喘患者的潜在影响。该研究领域的现有知识揭示了肠道和肺部微生物组与哮喘发展之间的相互作用。微生物组对哮喘药物药代动力学和药效学的影响是有限的；然而，了解这种相互作用将有助于创建更有效的治疗方法。本文献综述强调，在某些肠道细菌菌株存在的情况下，生物累积和生物转化可能会影响抗哮喘药物的药物代谢。此外，肺部和肠道中的细菌丰富度会影响药物的疗效，并且在药物反应中也可能发挥作用。上述发现的意义表明，微生物组是个体对抗哮喘药物的药物反应的一个影响因素。因此，未来的研究方向应该是调查这些过程如何影响哮喘患者，并考虑微生物组对药物疗效的作用，相应地修改治疗指南。
